Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fourth Dose of Boryung Cell-Culture Japanese Encephalitis Vaccine in Children
NCT02532569Phase 4Completed
- Sponsor
- Boryung
- Start
- Aug 2015
- Primary completion
- Oct 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of inactivated enterovirus 71 vaccine in Japanese encephalitis (JE), sponsored by Boryung. Primary endpoint: Seroconversion rates before and after the fourth dose of JEV at Day 28. Started Aug 2015; status: completed.
02
Drugs
inactivated enterovirus 71 vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on NCT02532569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02532569.